Annual Total Liabilities
$142.35 M
-$12.76 M-8.22%
November 30, 2024
Summary
- As of February 7, 2025, NRIX annual total liabilities is $142.35 million, with the most recent change of -$12.76 million (-8.22%) on November 30, 2024.
- During the last 3 years, NRIX annual total liabilities has risen by +$7.88 million (+5.86%).
- NRIX annual total liabilities is now -8.22% below its all-time high of $155.10 million, reached on November 30, 2023.
Performance
NRIX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$142.35 M
+$5.61 M+4.10%
November 30, 2024
Summary
- As of February 7, 2025, NRIX quarterly total liabilities is $142.35 million, with the most recent change of +$5.61 million (+4.10%) on November 30, 2024.
- Over the past year, NRIX quarterly total liabilities has dropped by -$1.58 million (-1.10%).
- NRIX quarterly total liabilities is now -8.22% below its all-time high of $155.10 million, reached on November 30, 2023.
Performance
NRIX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
NRIX Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -8.2% | -1.1% |
| 3 y3 years | +5.9% | +48.1% |
| 5 y5 years | +39.9% | +48.1% |
NRIX Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -8.2% | +25.9% | -8.2% | +91.4% |
| 5 y | 5-year | -8.2% | +39.9% | -8.2% | +91.4% |
| alltime | all time | -8.2% | +73.1% | -8.2% | +91.4% |
Nurix Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Nov 2024 | $142.35 M(-8.2%) | $142.35 M(+4.1%) |
| Aug 2024 | - | $136.74 M(-2.6%) |
| May 2024 | - | $140.34 M(-2.5%) |
| Feb 2024 | - | $143.93 M(-7.2%) |
| Nov 2023 | $155.10 M(+37.2%) | $155.10 M(+108.5%) |
| Aug 2023 | - | $74.38 M(-18.0%) |
| May 2023 | - | $90.70 M(-5.6%) |
| Feb 2023 | - | $96.10 M(-15.0%) |
| Nov 2022 | $113.06 M | $113.06 M(-3.2%) |
| Aug 2022 | - | $116.79 M(-8.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| May 2022 | - | $127.57 M(-3.2%) |
| Feb 2022 | - | $131.80 M(-2.0%) |
| Nov 2021 | $134.47 M(+26.8%) | $134.47 M(+14.1%) |
| Aug 2021 | - | $117.86 M(-1.6%) |
| May 2021 | - | $119.80 M(-5.3%) |
| Feb 2021 | - | $126.53 M(+19.3%) |
| Nov 2020 | $106.07 M(+4.2%) | $106.07 M(+1.7%) |
| Aug 2020 | - | $104.25 M(-2.3%) |
| May 2020 | - | $106.69 M(+4.8%) |
| Nov 2019 | $101.76 M(+23.7%) | $101.76 M |
| Nov 2018 | $82.24 M | - |
FAQ
- What is Nurix Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for Nurix Therapeutics?
- What is Nurix Therapeutics annual total liabilities year-on-year change?
- What is Nurix Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Nurix Therapeutics?
- What is Nurix Therapeutics quarterly total liabilities year-on-year change?
What is Nurix Therapeutics annual total liabilities?
The current annual total liabilities of NRIX is $142.35 M
What is the all time high annual total liabilities for Nurix Therapeutics?
Nurix Therapeutics all-time high annual total liabilities is $155.10 M
What is Nurix Therapeutics annual total liabilities year-on-year change?
Over the past year, NRIX annual total liabilities has changed by -$12.76 M (-8.22%)
What is Nurix Therapeutics quarterly total liabilities?
The current quarterly total liabilities of NRIX is $142.35 M
What is the all time high quarterly total liabilities for Nurix Therapeutics?
Nurix Therapeutics all-time high quarterly total liabilities is $155.10 M
What is Nurix Therapeutics quarterly total liabilities year-on-year change?
Over the past year, NRIX quarterly total liabilities has changed by -$1.58 M (-1.10%)